Cargando…
Activated protein C: cost-effective or costly?
The authors offer a commentary on the study by Dhainaut et al. on the cost-effectiveness of activated protein C in severe sepsis. Using data from "real world" conditions, the results of this economic evaluation are consistent with previous analyses, and highlight the need for "real wo...
Autores principales: | Brar, Savtaj Singh, Manns, Braden J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2556732/ https://www.ncbi.nlm.nih.gov/pubmed/17875223 http://dx.doi.org/10.1186/cc6090 |
Ejemplares similares
-
Drug costs in context: assessing drug costs in cost-of-illness analyses
por: Mattingly, T Joseph, et al.
Publicado: (2022) -
Issues of cost-benefit and cost-effectiveness for simulation in health professions education
por: Maloney, Stephen, et al.
Publicado: (2016) -
Mind the costs, too: towards better cost-effectiveness analyses of PBF programmes
por: Chi, Y-Ling, et al.
Publicado: (2018) -
Cost-effectiveness analysis for clinicians
por: Hill, Suzanne R
Publicado: (2012) -
The cost-effectiveness challenge: is it worth it?
por: Knapp, Martin
Publicado: (2015)